{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:02:11Z","timestamp":1786982531590,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University","award":["YX202106"],"award-info":[{"award-number":["YX202106"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30887"],"award-info":[{"award-number":["2022JJ30887"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Physiol Biochem"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s13105-026-01165-3","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:36:55Z","timestamp":1774946215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Odevixibat ameliorates high-fat diet-induced MASLD in mice by targeting the gut microbiota-metabolite axis and enhancing gut-liver crosstalk"],"prefix":"10.1007","volume":"82","author":[{"given":"Xiang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xulong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"publisher","first-page":"1081096","DOI":"10.3389\/fendo.2023.1081096","volume":"14","author":"XN Chai","year":"2023","unstructured":"Chai XN et al (2023) Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 14:1081096","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1165_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 71(4):793\u2013801","journal-title":"J Hepatol"},{"issue":"1","key":"1165_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jcb.29311","volume":"121","author":"J Chen","year":"2020","unstructured":"Chen J, Vitetta L (2020) Mitochondria could be a potential key mediator linking the intestinal microbiota to depression. J Cell Biochem 121(1):17\u201324","journal-title":"J Cell Biochem"},{"issue":"5","key":"1165_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J et al (2020) Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17(5):279\u2013297","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1165_CR5","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.31269","volume":"72","author":"J Chen","year":"2020","unstructured":"Chen J, Vitetta L (2020) Letter to the editor: could butyrate be incorporated with farnesoid X receptor agonist Cilofexor to enhance primary sclerosing cholangitis treatment? Hepatology 72(4):1497\u20131498","journal-title":"Hepatology"},{"key":"1165_CR6","doi-asserted-by":"crossref","unstructured":"Kolodziejczyk AA et al (2019) The role of the microbiome in NAFLD and NASH. EMBO Mol Med 11(2):e9302","DOI":"10.15252\/emmm.201809302"},{"issue":"12","key":"1165_CR7","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","volume":"62","author":"T Le Roy","year":"2013","unstructured":"Le Roy T et al (2013) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62(12):1787\u20131794","journal-title":"Gut"},{"issue":"1","key":"1165_CR8","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1038\/s41467-018-06929-0","volume":"9","author":"TK Soderborg","year":"2018","unstructured":"Soderborg TK et al (2018) The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun 9(1):4462","journal-title":"Nat Commun"},{"key":"1165_CR9","doi-asserted-by":"crossref","unstructured":"Chiu CC et al (2017) Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. Nutrients 9(11):1220","DOI":"10.3390\/nu9111220"},{"issue":"7","key":"1165_CR10","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","volume":"24","author":"L Hoyles","year":"2018","unstructured":"Hoyles L et al (2018) Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 24(7):1070\u20131080","journal-title":"Nat Med"},{"issue":"3","key":"1165_CR11","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","volume":"318","author":"JYL Chiang","year":"2020","unstructured":"Chiang JYL, Ferrell JM (2020) Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol 318(3):G554\u2013G573","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1165_CR12","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/jcb.27635","volume":"120","author":"J Chen","year":"2019","unstructured":"Chen J, Thomsen M, Vitetta L (2019) Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem 120(3):2713\u20132720","journal-title":"J Cell Biochem"},{"issue":"15","key":"1165_CR13","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s40265-021-01594-y","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED (2021) Odevixibat: first approval. Drugs 81(15):1781\u20131786","journal-title":"Drugs"},{"issue":"9","key":"1165_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","volume":"7","author":"RJ Thompson","year":"2022","unstructured":"Thompson RJ et al (2022) Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 7(9):830\u2013842","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1165_CR15","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.gastha.2024.100596","volume":"4","author":"S Yi","year":"2025","unstructured":"Yi S et al (2025) Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis. Gastro Hep Adv 4(4):100596","journal-title":"Gastro Hep Adv"},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"646113","DOI":"10.3389\/fcell.2021.646113","volume":"9","author":"R Li","year":"2021","unstructured":"Li R et al (2021) GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic \u03b2-Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux. Front Cell Dev Biol 9:646113","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"1165_CR17","doi-asserted-by":"publisher","first-page":"e12033","DOI":"10.1002\/ccs3.12033","volume":"18","author":"J Liao","year":"2024","unstructured":"Liao J et al (2024) LncRNA Snhg12\/IGFBP3 axis is involved in liver fibrosis by promoting the proliferation and activation of mouse hepatic stellate cells. J Cell Commun Signal 18(2):e12033","journal-title":"J Cell Commun Signal"},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"859292","DOI":"10.3389\/fnut.2022.859292","volume":"9","author":"J Varani","year":"2022","unstructured":"Varani J et al (2022) Liver Protein Expression in NASH Mice on a High-Fat Diet: Response to Multi-Mineral Intervention. Front Nutr 9:859292","journal-title":"Front Nutr"},{"issue":"8","key":"1165_CR19","first-page":"4557","volume":"7","author":"U Erben","year":"2014","unstructured":"Erben U et al (2014) A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol 7(8):4557\u20134576","journal-title":"Int J Clin Exp Pathol"},{"key":"1165_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14291","author":"Q Zhang","year":"2023","unstructured":"Zhang Q et al (2023) Changes in the gut microbiota of patients with Graves\u2019 orbitopathy according to severity grade. Clin Exp Ophthalmol. https:\/\/doi.org\/10.1111\/ceo.14291","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"1165_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","volume":"38","author":"GM Douglas","year":"2020","unstructured":"Douglas GM et al (2020) PICRUSt2 for prediction of metagenome functions. Nat Biotechnol 38(6):685\u2013688","journal-title":"Nat Biotechnol"},{"issue":"8","key":"1165_CR22","doi-asserted-by":"publisher","first-page":"100782","DOI":"10.1016\/j.jhepr.2023.100782","volume":"5","author":"RJ Thompson","year":"2023","unstructured":"Thompson RJ et al (2023) Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis. JHEP Rep 5(8):100782","journal-title":"JHEP Rep"},{"key":"1165_CR23","doi-asserted-by":"crossref","unstructured":"Peiseler M, Tacke F (2021) Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma. Cancers (Basel) 13(4):730","DOI":"10.3390\/cancers13040730"},{"issue":"6037","key":"1165_CR24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332(6037):1519\u20131523","journal-title":"Science"},{"issue":"4","key":"1165_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s13105-018-0628-y","volume":"74","author":"E Gatineau","year":"2018","unstructured":"Gatineau E et al (2018) Effect of high chronic intake of sucrose on liver metabolism in aging rats. Modulation by rutin and micronutrients. J Physiol Biochem 74(4):569\u2013577","journal-title":"J Physiol Biochem"},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"708959","DOI":"10.3389\/fimmu.2021.708959","volume":"12","author":"TCM Fontes-Cal","year":"2021","unstructured":"Fontes-Cal TCM et al (2021) Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. Front Immunol 12:708959","journal-title":"Front Immunol"},{"issue":"14","key":"1165_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/cells12141888","volume":"12","author":"L Shi","year":"2023","unstructured":"Shi L, Jin L, Huang W (2023) Bile Acids, Intestinal Barrier Dysfunction, and Related Diseases. Cells 12(14):1888","journal-title":"Cells"},{"key":"1165_CR28","doi-asserted-by":"crossref","unstructured":"Lai J et al (2023) Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Biomolecules 13(9):1356","DOI":"10.3390\/biom13091356"},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"108418","DOI":"10.1016\/j.diabres.2020.108418","volume":"169","author":"L Zhao","year":"2020","unstructured":"Zhao L et al (2020) Elevated levels of circulating short-chain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota. Diabetes Res Clin Pract 169:108418","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1165_CR30","doi-asserted-by":"publisher","first-page":"G906","DOI":"10.1152\/ajpgi.00043.2007","volume":"294","author":"F Raimondi","year":"2008","unstructured":"Raimondi F et al (2008) Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol 294(4):G906\u2013G913","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1165_CR31","doi-asserted-by":"publisher","first-page":"G227","DOI":"10.1152\/ajpgi.00267.2012","volume":"304","author":"LK Stenman","year":"2013","unstructured":"Stenman LK et al (2013) A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiology-Gastrointestinal Liver Physiol 304(3):G227\u2013G234","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"1165_CR32","doi-asserted-by":"publisher","first-page":"1120168","DOI":"10.3389\/fnut.2023.1120168","volume":"10","author":"Y Zhang","year":"2023","unstructured":"Zhang Y et al (2023) Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy. Front Nutr 10:1120168","journal-title":"Front Nutr"},{"key":"1165_CR33","doi-asserted-by":"crossref","unstructured":"Slavetinsky C, Sturm E (2020) Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis. BMJ Case Rep 13(6):e234185","DOI":"10.1136\/bcr-2019-234185"},{"issue":"5","key":"1165_CR34","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.clinre.2021.101751","volume":"45","author":"U Baumann","year":"2021","unstructured":"Baumann U et al (2021) Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. Clin Res Hepatol Gastroenterol 45(5):101751","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"1165_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/ibd\/izz266","volume":"26","author":"A Sayoc-Becerra","year":"2020","unstructured":"Sayoc-Becerra A et al (2020) The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction. Inflamm Bowel Dis 26(3):407\u2013422","journal-title":"Inflamm Bowel Dis"},{"key":"1165_CR36","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jhep.2020.11.013","volume":"75","author":"J Trebicka","year":"2021","unstructured":"Trebicka J et al (2021) The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 75:S67\u2013S81","journal-title":"J Hepatol"},{"issue":"4","key":"1165_CR37","doi-asserted-by":"publisher","first-page":"e0115521","DOI":"10.1128\/mBio.01155-21","volume":"12","author":"M Matsui","year":"2021","unstructured":"Matsui M et al (2021) Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. mBio 12(4):e0115521","journal-title":"mBio"},{"issue":"14","key":"1165_CR38","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1074\/jbc.RA119.011913","volume":"295","author":"S Takahashi","year":"2020","unstructured":"Takahashi S et al (2020) Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice. J Biol Chem 295(14):4733\u20134747","journal-title":"J Biol Chem"},{"issue":"40","key":"1165_CR39","doi-asserted-by":"publisher","first-page":"111409","DOI":"10.3748\/wjg.v31.i40.111409","volume":"31","author":"MA Anis","year":"2025","unstructured":"Anis MA et al (2025) Microbiome and gut-liver interactions: From mechanisms to therapies. World J Gastroenterol 31(40):111409","journal-title":"World J Gastroenterol"},{"key":"1165_CR40","doi-asserted-by":"crossref","unstructured":"Li Z et al (2023) The crosstalk between gut microbiota and bile acids promotes the development of non-alcoholic fatty liver disease. Microorganisms 11(8):2059","DOI":"10.3390\/microorganisms11082059"},{"issue":"1","key":"1165_CR41","doi-asserted-by":"publisher","first-page":"eaax6208","DOI":"10.1126\/sciadv.aax6208","volume":"6","author":"SL Zeng","year":"2020","unstructured":"Zeng SL et al (2020) Citrus polymethoxyflavones attenuate metabolic syndrome by regulating gut microbiome and amino acid metabolism. Sci Adv 6(1):eaax6208","journal-title":"Sci Adv"},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"1024722","DOI":"10.3389\/fnut.2022.1024722","volume":"9","author":"K Wang","year":"2022","unstructured":"Wang K et al (2022) Effects of essential oil extracted from Artemisia argyi leaf on lipid metabolism and gut microbiota in high-fat diet-fed mice. Front Nutr 9:1024722","journal-title":"Front Nutr"},{"issue":"2","key":"1165_CR43","doi-asserted-by":"publisher","first-page":"e0048421","DOI":"10.1128\/Spectrum.00484-21","volume":"9","author":"A Keshavarz","year":"2021","unstructured":"Keshavarz A, Raftar S et al (2021) The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD\/CCl4-Induced Liver Injury. Microbiol Spectr 9(2):e0048421","journal-title":"Microbiol Spectr"},{"issue":"5","key":"1165_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41564-021-00880-5","volume":"6","author":"HS Yoon","year":"2021","unstructured":"Yoon HS et al (2021) Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol 6(5):563\u2013573","journal-title":"Nat Microbiol"},{"issue":"4","key":"1165_CR45","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/mmi.14445","volume":"113","author":"CD Radka","year":"2020","unstructured":"Radka CD et al (2020) Fatty acid activation and utilization by Alistipes finegoldii, a representative Bacteroidetes resident of the human gut microbiome. Mol Microbiol 113(4):807\u2013825","journal-title":"Mol Microbiol"},{"issue":"2","key":"1165_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1574-6941.12228","volume":"87","author":"S Xiao","year":"2014","unstructured":"Xiao S et al (2014) A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 87(2):357\u2013367","journal-title":"FEMS Microbiol Ecol"},{"issue":"11","key":"1165_CR47","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00535-022-01909-0","volume":"57","author":"YC Lin","year":"2022","unstructured":"Lin YC et al (2022) Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity. J Gastroenterol 57(11):913\u2013925","journal-title":"J Gastroenterol"},{"issue":"8","key":"1165_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4254\/wjh.v12.i8.436","volume":"12","author":"S Kartsoli","year":"2020","unstructured":"Kartsoli S et al (2020) Lipidomics in non-alcoholic fatty liver disease. World J Hepatol 12(8):436\u2013450","journal-title":"World J Hepatol"},{"issue":"3","key":"1165_CR49","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/nu15030586","volume":"15","author":"X Jiang","year":"2023","unstructured":"Jiang X, Yang Q, Qu H, Chen Y, Zhu S (2023) Endogenous n-3 PUFAs improve non-alcoholic fatty liver disease through FFAR4-mediated gut-liver crosstalk. Nutrients 15(3):586","journal-title":"Nutrients"},{"issue":"5","key":"1165_CR50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/nu15051149","volume":"15","author":"C Yuan","year":"2023","unstructured":"Yuan C et al (2023) Integrated Analysis of Gut Microbiome and Liver Metabolome to Evaluate the Effects of Fecal Microbiota Transplantation on Lipopolysaccharide\/D-galactosamine-Induced Acute Liver Injury in Mice. Nutrients 15(5):1149","journal-title":"Nutrients"},{"issue":"5","key":"1165_CR51","first-page":"1149","volume":"20","author":"S-H Law","year":"2019","unstructured":"Law S-H et al (2019) Updated Rev Lysophosphatidylcholine Metabolism Hum Dis 20(5):1149","journal-title":"Updated Rev Lysophosphatidylcholine Metabolism Hum Dis"},{"key":"1165_CR52","doi-asserted-by":"crossref","unstructured":"Zhao Y et al (2023) Hypolipidemic mechanism of Pleurotus eryngii polysaccharides in high-fat diet-induced obese mice based on metabolomics. Front Nutr 10:p1118923","DOI":"10.3389\/fnut.2023.1118923"},{"key":"1165_CR53","doi-asserted-by":"crossref","unstructured":"Ha CY et al (2012) The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf) 76(5):674\u2013682","DOI":"10.1111\/j.1365-2265.2011.04244.x"},{"key":"1165_CR54","doi-asserted-by":"publisher","first-page":"140195","DOI":"10.1016\/j.foodchem.2024.140195","volume":"458","author":"G Ma","year":"2024","unstructured":"Ma G et al (2024) Metabolomics study of dietary Pleurotus eryngii \u03b2-type glycosidic polysaccharide on colitis induced by dextran sodium sulfate in mice \u2013 Exploration for the potential metabolic indicators in urine and serum. Food Chem 458:140195","journal-title":"Food Chem"},{"issue":"1","key":"1165_CR55","doi-asserted-by":"publisher","first-page":"2304159","DOI":"10.1080\/19490976.2024.2304159","volume":"16","author":"H Li","year":"2024","unstructured":"Li H et al (2024) Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosis through regulating gut microbial composition, gut-liver folate and unsaturated fatty acids metabolism. Gut Microbes 16(1):2304159","journal-title":"Gut Microbes"},{"issue":"1","key":"1165_CR56","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1038\/s41598-022-06414-1","volume":"12","author":"SKA Raftar","year":"2022","unstructured":"Raftar SKA et al (2022) The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD\/CCL4-induced murine model of liver injury. Sci Rep 12(1):2453","journal-title":"Sci Rep"},{"issue":"7","key":"1165_CR57","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.7150\/ijbs.81824","volume":"19","author":"H Chen","year":"2023","unstructured":"Chen H et al (2023) Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine. Int J Biol Sci 19(7):2097\u20132113","journal-title":"Int J Biol Sci"},{"key":"1165_CR58","doi-asserted-by":"publisher","first-page":"101231","DOI":"10.1016\/j.mam.2023.101231","volume":"95","author":"M Parola","year":"2024","unstructured":"Parola M, Pinzani M (2024) Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Mol Aspects Med 95:101231","journal-title":"Mol Aspects Med"}],"container-title":["Journal of Physiology and Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-026-01165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13105-026-01165-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-026-01165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:02:27Z","timestamp":1774951347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13105-026-01165-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s13105-026-01165-3","relation":{},"ISSN":["1138-7548","1877-8755"],"issn-type":[{"value":"1138-7548","type":"print"},{"value":"1877-8755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"All experiments involving animals were carried out under the approval of the Institutional Animal Care and Use Ethics Committee of The Third Xiangya Hospital, Central South University (Approval Number: LLSC(LA)2019-0003).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Animal ethics number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}